Search

Your search keyword '"Helmick, Ryan"' showing total 34 results
Start Over Author "Helmick, Ryan"
34 results on '"Helmick, Ryan"'

1. Unveiling APOL1 haplotypes in a predominantly African-American cohort of kidney transplant patients: a novel classification using probe-independent quantitative real-time PCR

Author

Dogan, Murat, primary, Watkins, Christine, additional, Ingram, Holly, additional, Moore, Nicholas, additional, Rucker, Grace M., additional, Gower, Elizabeth G., additional, Eason, James D., additional, Bhalla, Anshul, additional, Talwar, Manish, additional, Nezakatgoo, Nosratollah, additional, Eymard, Corey, additional, Helmick, Ryan, additional, Vanatta, Jason, additional, Bajwa, Amandeep, additional, Kuscu, Canan, additional, and Kuscu, Cem, additional

Published
2024
Full Text
View/download PDF

3. Transplantation of kidneys from hepatitis C–infected donors to hepatitis C–negative recipients: Single center experience

Author

Molnar, Miklos Z., Nair, Satheesh, Cseprekal, Orsolya, Yazawa, Masahiko, Talwar, Manish, Balaraman, Vasanthi, Podila, Pradeep S.B., Mas, Valeria, Maluf, Daniel, Helmick, Ryan A., Campos, Luis, Nezakatgoo, Nosratollah, Eymard, Corey, Horton, Peter, Verma, Rajanshu, Jenkins, Ann Holbrook, Handley, Charlotte R., Snyder, Heather S., Cummings, Carolyn, Agbim, Uchenna A., Maliakkal, Benedict, Satapathy, Sanjaya K., and Eason, James D.

Published
2019
Full Text
View/download PDF

4. Unveiling APOL1 Haplotypes: A Novel Classification Through Probe-Independent Quantitative Real-Time PCR

Author

Dogan, Murat, primary, Watkins, Christine, additional, Ingram, Holly, additional, Moore, Nicholas, additional, Rucker, Grace M., additional, Gower, Elizabeth G., additional, Eason, James D., additional, Bhalla, Anshul, additional, Talwar, Manish, additional, Nezakatgoo, Nosratollah, additional, Eymard, Corey, additional, Helmick, Ryan, additional, Vanatta, Jason, additional, Bajwa, Amandeep, additional, Kuscu, Canan, additional, and Kuscu, Cem, additional

Published
2023
Full Text
View/download PDF

6. A report of a prospective randomized trial of extended‐release tacrolimus versus immediate release tacrolimus after liver transplantation with anti‐thymocyte induction in a steroid free protocol.

Author

Helmick, Ryan A., Eymard, Corey M., Naik, Surabhi, Eason, James D., Nezakatgoo, Nosratollah, Nair, Satheesh, and Vanatta, Jason M.

Subjects
*LIVER transplantation, *TACROLIMUS, *KIDNEY transplantation, *GLOMERULAR filtration rate, *QUALITY of life
Abstract

Purpose: Our study hypothesis was that once daily dosing of extended‐release tacrolimus (XRT) would be a safe and effective immunosuppression (IS) with the potential to decrease adverse events (AEs) associated with immediate release tacrolimus (IRT) after liver transplantation (LT). Methods: All patients receiving LT at our center received rabbit anti‐thymocyte globulin (RATG) induction therapy. Eligible patients were randomized in a 1:1 fashion to receive either XRT or IRT. Antimicrobial prophylaxis was the same between arms, and both groups received an antimetabolite for the first 6 months following LT. Patients were then followed at pre‐determined study intervals for the following year after LT. We administered the RAND‐36SF survey to assess patient's health‐related quality of life at pre‐determined intervals. All analysis was performed with an intention to treat basis. Results: We screened 194 consecutive patients and enrolled 110. Our control and study arms were well matched. Transplant characteristics were similar between groups. At all timepoints, both arms had similar serum creatinine and estimated glomerular filtration rate (eGFR), calculated by MDRD6 equation, with post‐transplant GFRs between 60 and 70 mL/min/1.73 m2. Tacrolimus trough levels were similar between arms. The XRT arm had fewer AEs (166) and fewer serious AEs (70) compared to IRT (201 and 99, respectively). AEs most commonly were renal, infectious, or gastrointestinal in nature. While not statistically significant, XRT was held temporarily (25 vs. 35 cases) or discontinued (3 vs. 11 cases) less frequently than IRT and had fewer instances of rejection (7 vs. 12 cases). Conclusion: This analysis showed that XRT is safe and effective as de novo maintenance IS in a steroid‐free protocol with RATG. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Transplantation of liver from hepatitis C–infected donors to hepatitis C RNA–negative recipients: Histological and virologic outcome

Author

Nair, Satheesh P., primary, Marella, Hemnishil K., additional, Maliakkal, Benedict, additional, Snyder, Heather, additional, Handley, Charlotte, additional, Kothadia, Jiten P., additional, Ali, Bilal, additional, Satapathy, Sanjaya K., additional, Molnar, Miklos Z., additional, Clark, Ian, additional, Jain, Richa, additional, Helmick, Ryan, additional, Eymard, Corey, additional, and Eason, James D., additional

Published
2021
Full Text
View/download PDF

12. A pilot study of ex-vivo MRI-PDFF of donor livers for assessment of steatosis and predicting early graft dysfunction

Author

Satapathy, Sanjaya K., primary, Gonzalez, Humberto C., additional, Vanatta, Jason, additional, Dyer, Andrew, additional, Angel, Wesley, additional, Nouer, Simonne S., additional, Kocak, Mehmet, additional, Kedia, Satish K., additional, Jiang, Yu, additional, Clark, Ian, additional, Yadak, Nour, additional, Nezakagtoo, Nosratollah, additional, Helmick, Ryan, additional, Horton, Peter, additional, Campos, Luis, additional, Agbim, Uchenna, additional, Maliakkal, Benedict, additional, Maluf, Daniel, additional, Nair, Satheesh, additional, Halford, Hollis H., additional, and Eason, James D., additional

Published
2020
Full Text
View/download PDF

13. Lack of Association between Pretransplant Donor-Specific Antibodies and Posttransplant Kidney Outcomes in Simultaneous Liver-Kidney Transplant Recipients with Rabbit Anti-Thymocyte Globulin Induction and Steroid-Free Protocol

Author

Yazawa, Masahiko, primary, Cseprekal, Orsolya, additional, Helmick, Ryan A., additional, Talwar, Manish, additional, Balaraman, Vasanthi, additional, Podila, Pradeep S.B., additional, Agbim, Uchenna A., additional, Maliakkal, Benedict, additional, Fossey, Sallyanne, additional, Satapathy, Sanjaya K., additional, Sumida, Keiichi, additional, Kovesdy, Csaba P., additional, Nair, Satheesh, additional, Eason, James D., additional, and Molnar, Miklos Z., additional

Published
2020
Full Text
View/download PDF

14. Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients

Author

Yazawa, Masahiko, primary, Cseprekal, Orsolya, additional, Helmick, Ryan A., additional, Talwar, Manish, additional, Balaraman, Vasanthi, additional, Podila, Pradeep S. B., additional, Fossey, Sallyanne, additional, Satapathy, Sanjaya K., additional, Eason, James D., additional, and Molnar, Miklos Z., additional

Published
2019
Full Text
View/download PDF

15. Association between post‐transplant donor‐specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: single‐center, cohort study

Author

Yazawa, Masahiko, primary, Cseprekal, Orsolya, additional, Helmick, Ryan A., additional, Talwar, Manish, additional, Balaraman, Vasanthi, additional, Podila, Pradeep S. B., additional, Agbim, Uchenna A., additional, Maliakkal, Benedict, additional, Fossey, Sallyanne, additional, Satapathy, Sanjaya K., additional, Sumida, Keiichi, additional, Kovesdy, Csaba P., additional, Nair, Satheesh, additional, Eason, James D., additional, and Molnar, Miklos Z., additional

Published
2019
Full Text
View/download PDF

18. Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients

Author

Yazawa, Masahiko, Cseprekal, Orsolya, Helmick, Ryan A., Talwar, Manish, Balaraman, Vasanthi, Podila, Pradeep S. B., Fossey, Sallyanne, Satapathy, Sanjaya K., Eason, James D., and Molnar, Miklos Z.

Abstract

De novo Donor Specific Antibodies (DSA) are considered as a risk factor for the kidney allograft outcomes in recipients after simultaneous liver–kidney transplantation (SLKT). We hypothesized that length of hospital stay (LOS) might be associated with de novo DSA development of due to the increased likelihood of receiving blood transfusions with reduced immunosuppressive regimens. This study is a single-center, retrospective cohort study consisting of 85 recipients who underwent SLKT from 2009 to 2018 in our hospital. We divided the patients into two groups according to LOS [long hospital stay (L) group (LOS >14 days) and short hospital stay (S) group (LOS ≤14 days)]. Propensity score (PS) has been created using logistic regression to predict LOS greater than median of 14 days. The association between the presence of de novo DSA and LOS was assessed by logistic regression models adjusted for PS. The mean age at transplantation of the entire cohort was 55.5 ± 10.1 years. Sixty percent of the recipients were male and Caucasian. Median LOS in (L) group was three-fold longer than (S) group [L: median 30 days (IQR: 21–52), S: median 8.5 days (IQR: 7–11)]. Eight patients developed de novo DSA after SLKT (9.4%), all of them were in (L) group. Longer LOS was significantly associated with higher risk of development of de novo DSA in unadjusted (OR+ each 5 days: 1.09, 95% CI:1.02–1.16) and PS adjusted (OR+ each 5 days: 1.11, 95% CI:1.02–1.21) analysis. Longer hospitalization is significantly associated with the development of de novo DSA in SLKT.

Published
2019
Full Text
View/download PDF

21. Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver–kidney transplant recipients.

Author

Yazawa, Masahiko, Cseprekal, Orsolya, Helmick, Ryan A., Talwar, Manish, Balaraman, Vasanthi, Podila, Pradeep S. B., Fossey, Sallyanne, Satapathy, Sanjaya K., Eason, James D., and Molnar, Miklos Z.

Subjects
LENGTH of stay in hospitals, HOSPITAL care, IMMUNOGLOBULINS, LOGISTIC regression analysis, BLOOD transfusion
Abstract

De novo Donor Specific Antibodies (DSA) are considered as a risk factor for the kidney allograft outcomes in recipients after simultaneous liver–kidney transplantation (SLKT). We hypothesized that length of hospital stay (LOS) might be associated with de novo DSA development of due to the increased likelihood of receiving blood transfusions with reduced immunosuppressive regimens. This study is a single-center, retrospective cohort study consisting of 85 recipients who underwent SLKT from 2009 to 2018 in our hospital. We divided the patients into two groups according to LOS [long hospital stay (L) group (LOS >14 days) and short hospital stay (S) group (LOS ≤14 days)]. Propensity score (PS) has been created using logistic regression to predict LOS greater than median of 14 days. The association between the presence of de novo DSA and LOS was assessed by logistic regression models adjusted for PS. The mean age at transplantation of the entire cohort was 55.5 ± 10.1 years. Sixty percent of the recipients were male and Caucasian. Median LOS in (L) group was three-fold longer than (S) group [L: median 30 days (IQR: 21–52), S: median 8.5 days (IQR: 7–11)]. Eight patients developed de novo DSA after SLKT (9.4%), all of them were in (L) group. Longer LOS was significantly associated with higher risk of development of de novo DSA in unadjusted (OR+ each 5 days: 1.09, 95% CI:1.02–1.16) and PS adjusted (OR+ each 5 days: 1.11, 95% CI:1.02–1.21) analysis. Longer hospitalization is significantly associated with the development of de novo DSA in SLKT. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

22. Association between post‐transplant donor‐specific antibodies and recipient outcomes in simultaneous liver–kidney transplant recipients: single‐center, cohort study.

Author

Yazawa, Masahiko, Cseprekal, Orsolya, Helmick, Ryan A., Talwar, Manish, Balaraman, Vasanthi, Podila, Pradeep S. B., Agbim, Uchenna A., Maliakkal, Benedict, Fossey, Sallyanne, Satapathy, Sanjaya K., Sumida, Keiichi, Kovesdy, Csaba P., Nair, Satheesh, Eason, James D., and Molnar, Miklos Z.

Subjects
COHORT analysis, IMMUNOGLOBULINS, TRANSPLANTATION of organs, tissues, etc., PROPORTIONAL hazards models, REGRESSION analysis
Abstract

Summary: There is a dearth of published data regarding the presence of post‐transplant donor‐specific antibodies (DSA), especially C1q‐binding DSA (C1q+DSA), and patient and kidney allograft outcomes in simultaneous liver–kidney transplant (SLKT) recipients. We conducted a retrospective cohort study consisted of 85 consecutive SLKT patients between 2009 and 2018 in our center. Associations between presence of post‐transplant DSA, including persistent and/or newly developed DSA and C1q+DSA, and all‐cause mortality and the composite outcome of mortality, allograft kidney loss, and antibody‐mediated rejection were examined using unadjusted and age and sex‐adjusted Cox proportional hazards and time‐dependent regression models. The mean age at SLKT was 56 years and 60% of the patients were male. Twelve patients (14%) had post‐transplant DSA and seven patients (8%) had C1q+DSA. The presence of post‐transplant DSA was significantly associated with increased risk of mortality (unadjusted model: Hazard Ratio (HR) = 2.72, 95% confidence interval (CI): 1.06–6.98 and adjusted model: HR = 3.20, 95% CI: 1.11–9.22) and the composite outcome (unadjusted model: HR = 3.18, 95% CI: 1.31–7.68 and adjusted model: HR = 3.93, 95% CI: 1.39–11.10). There was also higher risk for outcomes in recipients with C1q+DSA compared the ones without C1q+DSA. Post‐transplant DSA is significantly associated with worse patient and kidney allograft outcomes in SLKT. Further prospective and large cohort studies are warranted to better assess these associations. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

34. Unveiling APOL1 Haplotypes: A Novel Classification Through Probe-Independent Quantitative Real-Time PCR.

Author

Dogan M, Watkins C, Ingram H, Moore N, Rucker GM, Gower EG, Eason JD, Bhalla A, Talwar M, Nezakatgoo N, Eymard C, Helmick R, Vanatta J, Bajwa A, Kuscu C, and Kuscu C

Abstract

Introduction: Apolipoprotein-L1 (APOL1) is a primate-specific protein component of high- density lipoprotein (HDL). Two variants of APOL1 (G1 and G2), provide resistance to parasitic infections in African Americans but are also implicated in kidney-related diseases and transplant outcomes in recipients. This study aims to identify these risk variants using a novel probe- independent quantitative real-time PCR method in a high African American recipient cohort. Additionally, it aims to develop a new stratification approach based on haplotype-centric model., Methods: Genomic DNA was extracted from recipient PBMCs using SDS lysis buffer and proteinase K. Quantitative PCR assay with modified forward primers and a common reverse primer enabled us to identify single nucleotide polymorphisms (SNPs) and the 6-bp deletion quantitatively. Additionally, we used sanger sequencing to verify our QPCR findings., Results: Our novel probe-independent qPCR effectively distinguished homozygous wild-type, heterozygous SNPs/deletion, and homozygous SNPs/deletion, with at least 4-fold differences. High prevalence of APOL1 variants was observed (18% two-risk alleles, 34% one-risk allele) in our recipient cohort. Intriguingly, up to 12-month follow-up revealed no significant impact of recipient APOL1 variants on transplant outcomes. Ongoing research will encompass more time points and a larger patient cohort, allowing a comprehensive evaluation of G1/G2 variant subgroups categorized by new haplotype scores, enriching our understanding., Conclusions: Our cost-effective and rapid qPCR technique facilitates APOL1 genotyping within hours. Prospective and retrospective studies will enable comparisons with long-term allograft rejection, potentially predicting early/late-stage transplant outcomes based on haplotype evaluation in this diverse group of kidney transplant recipients.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results